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Europe encompasses a very large but
diverse EP community, including physicians with
various backgrounds and specialities coming
from many countries and centres, with inherent
differences regarding clinical practice, imple-
mentation of guidelines and their legal implica-
tion, access to modern therapies, and health
economic systems.
Ideally, patient registries can capture such
differences in patient management and thereby
improve quality of care. Registries are, however,
often associated with significant efforts and cost
for the healthcare community, and seldom gives
a quick insight into the clinical practice or their
adoption to guidelines. As the Scientific Initiative
Committee of the European Heart Rhythm
Association (EHRA), we have continued to
publish the so-called ‘EP wires’. These are
surveys, consisting of short questionnaires with
15–25 questions, accessible via the Internet
for centres which voluntarily has declared their
interest to participate in EHRA’s, Electrophysi-
ology (EP) Network. The aim with these EP
Wire surveys is to provide a quick insight into
current clinical practice and adoption to guide-
lines in the EP community in Europe. Well
aware of and recognising the limitations with
these surveys, it is our believe that by spreading
the results and demonstrating regional and/or
geographical differences regarding use or access
to modern therapies, it may hopefully improve
the situations for many of our patients and
colleagues. Such surveys may also recognize
unmet needs for education.
The aim of this specific EP Wire survey was to
provide insight intocurrentpracticeregarding the
management ofpaediatric arrhythmias inEurope.
The survey was based on a questionnaire sent via
the Internet to the EHRA, EP Network Centres.
We did not intend to analyse practice among
paediatric EP centres exclusively. Furthermore,
surveys can only reflect the past and what is
asked for in a limited number of centres. We
do,however, welcome theparticipation ofpaedi-
atric EP centres and the EP network can be
reached on our website.
Our results are based on the non-paediatric
EP community and in the results we stated:
‘Catheter ablation of paediatric arrhythmias
was exclusively performed by paediatric elec-
trophysiologists in only 2.56% of the centres,
while EP teams were multidisciplinary in
15.36% of hospitals or the same teams per-
formed ablations in both children and adult
patients (82.05%)’. This means that most
centres do perform paediatric ablation, even if
they may not be the ‘centres only specialized
in paediatric arrhythmias’. We believe it is
quite common in Europe.
Given the limitations with both surveys and
registries, the formerbeing basedon physician’s
perception and the latter most often being on a
voluntary basis, we still believe that many of
these EP wires and registries contribute to an
increased awareness of differences in health-
care and educational needs.
Correct that none of the authors are
paediatric cardiologist, and electrophysiolo-
gists only but many with wide experience in
paediatric catheter ablation procedures and
related publications.3 The volume of ablation
procedures performed is the key for a high
quality. We believe that our survey supports
the need for a continued collaboration with
the paediatric EP community and we welcome
a corresponding survey, or a Registry, involving
ALL centres performing paediatric ablations.
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Left atrial appendage closure
to prevent stroke in patients
with atrial fibrillation: a call
for the heart team approach
With great interest we read the EHRA/EAPCI
expert consensus statement on catheter-based
left atrial appendage (LAA) occlusion.1 It is
important to emphasize that the seminal efforts
to address the LAA originate from open-heart
surgery, specifically Madden’s seminal report
on surgical LAA amputation in 1949, which has
driven innovation and the development of less
invasive catheter-based approaches to achieve
LAA closure.
Current data have led to early clinical adop-
tion of this seemingly attractive therapy. In this
regard, the incorporation of surgically applied
epicardial closure devices may offer an interest-
ing adjunct for selected patients. Unfortunately,
the expert panel just states that ‘. . .. In addition,
a number of other minimally invasive surgical
and percutaneous devices including the AtriClip,
Cardioablate, and Aegis, are at various stages of
advanced animal studies or first in man experi-
ments . . .’.1
We believe it is important to also include the
surgical devices in this statement. The clinical ex-
perience with these surgically placed devices is
substantial and can be found in many peer
reviewed journals. First, the AtriClip has been
implanted in humans since 2007. Over 40 000
devices have been sold since CE mark and
FDA approval. Data on this effective device are
substantial.2,3 Next, the long-term imaging con-
trolled data on the AtriClip further substantiate
these positive results of complete and durable
closure, presenting the first data on durability
ofLAA closure.3 Second, there is an anotherepi-
cardial closuredevice, theTiger-Paw(MAQUET
Medical Systems USA, Wayne, NJ, USA) appro-
ved by the FDA yielding similar short-term
safety and efficacy results as the aforementioned
AtriClip (Atricure, West Chester, OH, USA).4
Third, and most importantly, thoracoscopic
LAA amputation with 3 months computed tom-
ography control with a linear stapler has been
reported in a stand-alone fashion by Ohtsuka
et al.5 LAA stapler amputation has long been an
integral part of surgical minimal invasive atrial
fibrillation ablation. The results are summarized
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in two review papers, reporting on over 1000
patients also highlight feasibility, safety and effi-
cacy of routine surgical LAA amputation.6
Before any type of intervention, important
anatomical and morphological considerations
are mandatory to more accurately predict in
which patients a complete and durable trans-
catheter closure is not likely to be achieved. In
these cases, referral for minimally invasive surgi-
cal LAA closure should be considered as an
option.Webelieve thatonlyamore focusedcol-
laboration between cardiologists and cardio-
thoracic surgeons (the heart team approach) in
regard to device and patient selection would
enable a 100% successful LAA closure in all-
comers. In regards to stroke prevention obviously
more data, and ideally a prospective randomized
trial would be necessary.
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